DBV Technologies (DBVT) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $21.52
• Market Cap: $1.22B
• EPS: $-5.20
• 52-Week High: $26.18
• 52-Week Low: $3.82

Market Sentiment

DBV Technologies currently has a Bullish sentiment score of 0.31.

About DBV Technologies

DBV Technologies SA (DBVT) is a clinical-stage biopharmaceutical company headquartered in Montrouge, France, specializing in the development of novel epicutaneous immunotherapy products for the treatment of food allergies. Utilizing its proprietary Viaskin™ technology platform, DBV aims to provide non-invasive treatment solutions that facilitate allergen desensitization, significantly improving patient quality of life. The company’s robust pipeline, which includes lead candidates specifically...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for DBV Technologies and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does DBVT pay dividends?

DBV Technologies (DBVT) does not currently pay a regular dividend.

What is DBVT's market cap?

DBV Technologies (DBVT) has a market capitalization of $1.22B with a current stock price of $21.52.